Skip to main content
Category

News Archive

astra-zeneca-full-logo

AstraZeneca Supports Alderley Park Incubation Fund – Labmate Online

By News Archive

astra-zeneca-full-logo

BioCity, the incubation specialist with locations in the East Midlands, North West and Scotland has announced a new investment fund, created following a significant contribution by AstraZeneca.

The £5 million fund, to be managed by BioCity will make equity investments, typically between £50,000 and £250,000, in life science companies based at Alderley Park, Cheshire. BioCity Chairman, Dr Louis Nisbet explains: “We are very pleased that AstraZeneca has chosen BioCity to manage these funds, not only to support the growth of a new generation of life science businesses at Alderley Park but also to make sound investment decisions that aim to replenish and grow this evergreen fund over time.”

Read More
cdvca-logo

2015 Annual Conference – The Community Development Venture Capital Alliance

By News Archive

cdvca-logo

CDVCA is organizing its 20th anniversary Annual Conference in Washington, DC on March 18-20, 2015 in Washington, DC. CDVCA’s Annual Conference is the premier training and networking event for anyone interested in developmental venture capital, including social VC fund managers, emerging fund managers, investors, economic development professionals, foundations representatives, policy makers, government officials and aspiring students.

Read More
bioit-solution-logo

BioIT Solutions among the 20 Most Promising Biotechnology Solutions for 2014 – BioIT Solutions

By News Archive

bioit-solution-logo

BioIT Solutions, a provider of enterprise systems built on the 1Platform4™ product suite, today announced that CIO Review has chosen BioIT Solutions as one of its 20 Most Promising Biotechnology Solution providers.

BioIT Solutions was selected for its expertise in providing data management solutions for biotech research, drug development, and diagnostics. The annual list of companies is selected by a panel of experts and members of CIO Review’s editorial board to recognize and promote technology entrepreneurship.

Read More
nhlbi-logo-new.png

February Funding Deadlines in Cystic Fibrosis, Microfluidic Platforms, and Stem Cell-Derived Blood Product Technologies

By News Archive

nhlbi-logo-new.png

The National Heart, Lung, and Blood Institute (NHLBI) has 3 targeted funding opportunities with deadlines in February. It’s also not too early to start preparing for the April 5 Omnibus solicitation deadline. Check your registrations (SAM must be renewed annually!) and reach out to discuss your project.

For questions about the NHLBI SBIR/STTR programs, contact Small Business Coordinator Jennifer Shieh, PhD at NHLBI_SBIR@mail.nih.gov

Human Cellular Models for Predicting Individual Responses to CFTR-Directed Therapeutics— Due February 9

For the development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis lung disease.

SBIR:
RFA-HL-15-027 STTR: RFA-HL-15-026

For questions about these funding opportunities, contact:
Robert Smith, PhD, robert.smith4@nih.gov
Program Director, Division of Lung Diseases

Development of a Microfluidic Platform for Blood Testing in Neonatal & Pediatric Patients— Due February 10 (Phase II only)

For the development of microfluidic devices to analyze blood for factors related to the thrombotic, transfusion, and/or hemostatic status of pediatric/neonatal patients.

SBIR—Phase II only: RFA-HL-14-026
This application must be based on an awarded SBIR or STTR-funded Phase I project.

For questions about this funding opportunity, contact:
Ronald Warren, PhD, rwarren@nhlbi.nih.gov
Program Director, Division of Blood Diseases and Resources

Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement— Due February 20

For tools and technologies that enable further advances in the manufacturing process to produce safe and functional blood and platelet products at reduced costs.

SBIR: RFA-HL-15-030 STTR: RFA-HL-15-029

Slides from the January 8 webinar are available—please send a request to NHLBI_SBIR@mail.nih.gov.

For questions about these funding opportunities, contact:
Shimian Zou, PhD, shimian.zou@nih.gov
Program Director, Division of Blood Diseases and Resources

John Thomas, PhD, thomasj@nhlbi.nih.gov
Program Director, Division of Blood Diseases and Resources

startup-maryland-logo-white

Startup Maryland Announces Shahab Kaviani as Entrepreneur-in-Residence

By News Archive

startup-maryland-logo-white

Startup Maryland (www.startupmd.org) today announced appointment of serial entrepreneur Shahab Kaviani as Entrepreneur-in-Residence (EiR).

A recognized leader of startup communities globally, Kaviani brings over a decade of first-hand entrepreneurial expertise and leadership experience most-recently as co-founder and CEO of Rockville, MD based CoFoundersLab (now Onevest). Previously, Kaviani served on the executive management team growing another Maryland company, HyperOffice, into a cloud-collaboration software leader.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.